Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 2/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | TDO2 | P48775 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.33 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
| ▸ | RET | P07949 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
| ▸ | TNF | P01375 | 2/20 | 0.32 |
| ▸ | LITAF | Q99732 | 2/20 | 0.32 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21050747 | 0.89 | KRAS (0.43) | KRAS | |
| SCHEMBL21099612 | 0.88 | KRAS (0.50) | KRASGPR119IDO1TDO2SCN9A | |
| SCHEMBL21099329 | 0.84 | KRAS (0.63) | KRASSCN9A | |
| SCHEMBL21099346 | 0.82 | KRAS (0.55) | KRAS | |
| SCHEMBL21050914 | 0.79 | KRAS (0.52) | KRASGPR119IDO1TDO2 | |
| SCHEMBL21099365 | 0.79 | KRAS (0.49) | KRASGPR119IDO1TDO2RET | |
| SCHEMBL21136846 | 0.78 | KRAS (0.51) | KRASGPR119TNFLITAF | |
| SCHEMBL21099582 | 0.78 | KRAS (0.51) | KRASGPR119TNFLITAF | |
| SCHEMBL21136786 | 0.78 | CCNE2 (0.32) | — | |
| SCHEMBL21099999 | 0.78 | KRAS (0.51) | KRASGPR119TNFLITAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019110751-A1 | TETRACYCLIC COMPOUNDS AS INHIBITORS OF G12C MUTANT RAS PROTEIN, FOR USE AS ANTI-CANCER AGENTS | ASTRAZENECA AB (SE) | 2019-06-13 | — | — | WO | disclosed |
| US-20190177338-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2019-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190177338-A1 | CHEMICAL COMPOUNDS | MKI67, CCNI, MCL1 | KRAS 272/4885GPR119 945/4885IDO1 3705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.